<DOC>
	<DOC>NCT01960205</DOC>
	<brief_summary>The purpose of the study is to examine the effect of Saxagliptin in the newly diagnosed people with pre-diabetes and obesity besides lifestyle intervention ,there to evaluate DPP 4 inhibitors of reversing pre-diabetes curative effect to normal blood sugar, and observe its influences on the targets of obesity related metabolic abnormalities, to explore new ways for intervention on populations with pre-diabetes and obesity .</brief_summary>
	<brief_title>Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity</brief_title>
	<detailed_description>Materials and Methods: This is a perspectiveness ,randomized, opening study, patients will be randomly assigned to the standarddose Saxagliptin group ,the lifestyle intervention group,the Metformin group and the low dose Saxagliptin group with a 6-month treatment period. Oral glucose tolerance test will examined before and 6 months post-treatment during the trial.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1.Newly diagnosed insulin resistance or glucose intolerance . 2.20 to 70 years of age. 3.BMI≥28kg/m2，or BMI＞25kg/m2 beside waistline≥80cm（female)，≥90cm(male). 1. Under Diabetes Mellitus treatment. 2. Allergy to dipeptidyl peptidase 4 (DPP4) inhibitors . 3. Active heart failure. 4. Unwilling or unable to sign inform consents.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Saxagliptin, prediabetes, glucose intolerance,obesity</keyword>
</DOC>